Kymera Therapeutics (KYMR) Expected to Announce Quarterly Earnings on Thursday

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Kymera Therapeutics to post earnings of ($0.77) per share and revenue of $14.81 million for the quarter. Individual interested in registering for the company's earnings conference call can do so using this link.

Kymera Therapeutics Stock Down 2.7 %

Shares of KYMR traded down $1.03 during trading hours on Friday, hitting $36.40. The company had a trading volume of 171,450 shares, compared to its average volume of 480,967. The firm has a market cap of $2.36 billion, a P/E ratio of -15.60 and a beta of 2.18. The stock's 50 day moving average price is $39.88 and its 200 day moving average price is $44.04. Kymera Therapeutics has a 52-week low of $29.24 and a 52-week high of $53.27.

Insider Transactions at Kymera Therapeutics

In other news, insider Ellen Chiniara sold 3,129 shares of the business's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $41.75, for a total value of $130,635.75. Following the sale, the insider now directly owns 54,826 shares of the company's stock, valued at $2,288,985.50. The trade was a 5.40 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 15.82% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Wells Fargo & Company upgraded Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $38.00 to $57.00 in a report on Monday, December 2nd. BMO Capital Markets initiated coverage on Kymera Therapeutics in a research note on Friday, December 6th. They issued a "market perform" rating and a $55.00 target price on the stock. Morgan Stanley raised their target price on Kymera Therapeutics from $45.00 to $49.00 and gave the stock an "equal weight" rating in a research note on Wednesday, November 6th. Guggenheim raised their target price on Kymera Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a research note on Friday, November 1st. Finally, Leerink Partners reissued an "outperform" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $55.06.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.